Products for Research Use Only

Dolastatin 10

CAT: 0804-HY-15580-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15580-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Dolastatin 10 (DLS 10) is a potent antimitotic peptide that inhibits tubulin polymerization.
CAS Number
110417-88-4
Product Name Alternative
DLS 10; NSC 376128
UNSPSC
12352209
Hazard Statement
H302, H315, H319, H335
Target
ADC Payload; Microtubule/Tubulin
Type
Natural Products
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Dolastatin-10.html
Purity
98.11
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C([C@H](C)[C@H]([C@]1([H])CCCN1C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C([C@@H](NC([C@@H](N(C)C)C(C)C)=O)C(C)C)=O)C)=O)OC)N[C@@H](CC2=CC=CC=C2)C3=NC=CS3
Molecular Formula
C42H68N6O6S
Molecular Weight
785.09
Precautions
H302, H315, H319, H335
References & Citations
[1]Pitot HC, et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 1999 Mar;5 (3) :525-31.|[2]Pettit GR, et al. Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications ofdolastatin 10. J Nat Prod. 2011 May 27;74 (5) :962-8.|[3]Brentuximab vedotin. Drugs R D. 2011;11 (1) :85-95.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Natural Products
Clinical Information
Phase 2
Isoform
Auristatin